Glaxo announced disappointing 1QCY05 numbers much in line with its peers in the industry. In the following article, we take a look at how the company has performed over the years and future prospects.
About the company
Numbers at a glance...
Net sales growth (%)
Operating profit margin (%)
PBT margin (%)
Net profit margin (%)
Net profit growth (%)
GSK India is the largest pharma company in the Indian market with a share of 6.5% (December 2004). It is a 49% subsidiary of US$ 37 bn Glaxo group - the world's second largest pharma company with a R&D war chest of US$ 4 bn. GSK India's product portfolio boasts of some of the leading brands like Augmentin, Zinetac, Betnesol, Cobadex Forte and Zevit in the domestic pharma market. Most of the company's products face stiff price competition from domestic players. The company underwent a restructuring exercise and effect of the same was evident in 2003 and 2004. It derives its revenues from pharmaceuticals, animal healthcare and fine chemicals. In 2004, it successfully merged Burroughs Wellcome India with itself, after a long wait.
Performance over the years CY02: Topline registered a sluggish 4% YoY growth. Though the pharma business recorded an 8.5% growth, which was in line with the industry trend, the allied businesses registered a decline of over 7% in revenues, leading to a staid topline growth. However, it must be noted that the company's efforts to reduce costs and thereby improve operating margins from 10% to 16% augured well for the company, negating the impact of sluggish revenues. Raw material costs and other expenses dropped by 5% YoY and 3% YoY respectively.
Raw materials consumed
The management also made a decision to concentrate on its top 30 brands in a bid to boost its profitability. Also, the company's decision to close down unviable plants and sell property of the erstwhile SmithKline led to a drop in its depreciation provisioning. Consequently, bottomline soared by 123% YoY. However, if one were to exclude the effect of the extraordinary items, bottomline actually grew by 70% YoY.
CY03: During the year topline registered a 4% YoY growth. This topline growth was mainly driven by the pharmaceuticals business which grew 6% YoY. The company's strategy of focusing on 30 priority brands (including brands like 'Augmentin') ensured that these products registered a double-digit growth and consequently, boosted the revenues of the pharma business. Another growth driver was the company's vaccines range where it rolled out a concept of 'Famili Vaccines', an immunisation awareness initiative.
Net sales growth (%)
Operating profit margin (%)
Net profit margin (%)
* November 2004
The company also focused on enhancing its operational efficiency, which was reflected in the rise in the operating margins from 17% to 23%. Raw material costs and other expenses (as a percentage of sales) registered a decline of 2% and 8% respectively. This was consequently reflected in the bottomline which rose by 51% YoY. The improvement in the margins would have been better but for the fact that the National Pharmaceuticals Pricing Authority (NPPA) revised downwards the prices of Ranitidine formulations in September 2003. This affected the margins of Zinetac, one of the important products of Glaxo.
CY04: Revenues clocked a robust 26% YoY growth. However, it must be noted that during the year, the company merged Burroughs Wellcome India with itself, which contributed around 14% to Glaxo's revenues. If Burroughs is excluded, then the revenues grew by 8% YoY. The company's pharma business (84% to revenues in CY04), grew by 8.7%, beating the industry growth rate of 6.4%. The growth was led by the company's continued focus on power brands. As far as the other businesses are concerned, animal health business grew by 7% and the fine chemicals business grew by 5.5%.
Operating margins showed considerable improvement from 23% to 28% on the back of increased contribution from power brands as well as lower marketing, sales promotion and administrative expenses. This was also reflected in the bottomline which jumped 93% YoY. However, the sharp rise in the bottomline was also due to the extraordinary income fillip during the year to the tune of Rs 670 m, which was on account of sale of its Worli plot.
What to expect?
At 768, the stock is trading at a P/E multiple of 35.7 its annualised 1QCY05 earnings. In our view, Glaxo has restructured itself well so far. The company has focused itself on its power brands and is likely to dominate these categories going forward. Glaxo will soon be entering growing market segments like cardiovascular, CNS and diabetes. It is exploring in-licensing opportunities in the gynaecology, gastroenterology and nutritional segments. Going forward, the company is also likely to start clinical trials, which shows that the Indian subsidiary is high on the parent's radar. Also, now that the product patent regime has come into force in India, the company is set to launch new patented products from its parent's portfolio (after 2007).
The company reported subdued 1QFY05 numbers due to VAT and MRP based excise related concerns. We expect CY05 also to be a subdued year. Also, though beneficial in the long term, the impact of the product patent regime is not likely to have an immediate impact on growth. Having said that, prospects for the company look good from a long-term perspective.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407